Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

ARREST-TB · Accurate, Rapid, Robust and Economical diagnostic technoliogieS for Tuberculosis

H2020Status: CLOSED1 January 201930 June 2021EU funding €2,997,496Call H2020-SC1-BHC-2018-2020

This visionary project addresses the key needs of patients, clinicians and the World Health Organisations stated deliverables of affordable, reliable and point-of-care molecular TB diagnostics, with the vision of removing the need for centralised facilities and offering remote primary care diagnosis coupled with telemetry for “cloud based” notification to ensure public health and surveillance interventions. The core technology deliverables will include: Rapid screening of TB infection (within 30 mins): We will develop low-cost portable optical devices and chemical molecular probes for accurate and rapid ‘triage tests’ to allow ‘no-wash’ detection of Mycobacteria ‘in-field’ in sputum at costs comparable with or lower than existing microscopy-based methods. This technology has the aim of replacing current sputum-based microscopy methods. Rapid molecular identification of drug resistance (within 2 hours): We will develop novel low-cost assays based on molecular methods that will allow accurate and rapid screening for the Mycobacterium tuberculosis complex in sputum and drug-resistant tuberculosis, thus providing rapid screening of at risk groups for TB as well as identification of drug resistance profiles. Biomarkers for early diagnosis and assessing treatment response: A higher risk element is the development of point-of-care diagnostics for quantification of microRNAs (that are known to be modulated during progression from latent to active TB and during treatment progression), directly from small blood samples. We will ensure that the technologies are economically viable in the context of resource poor settings – indeed the whole project will be driven by practical need and local resourcing constraints – NOT imposition. Thus it will require negligible initial costs for implementation, minimal training and expertise, with the running costs less than 1/10 th of current detection technologies, thereby addressing a key objective of the work program.

Consortium · 9 organisations

coordinator

THE UNIVERSITY OF EDINBURGH

UK · €1,031,683

participant

OPTOELETTRONICA ITALIA SRL

IT · €271,250

participant

GENETIC ANALYSIS STRATEGIES SL

ES · €292,450

participant

UNIVERSITA DEGLI STUDI DI PADOVA

IT · €391,750

participant

SHANMUKHA INNOVATIONS PRIVATE LIMITED

IN

participant

HERIOT-WATT UNIVERSITY

UK · €592,453

participant

DESTINA GENOMICA SLNE

ES · €417,911

participant

INDIAN COUNCIL OF MEDICAL RESEARCHSOCIETY

IN

participant

CENTRAL TUBERCULOSIS RESEARCH INSTITUTE OF RUSSIAN ACADEMY OF MEDICAL SCIENCES

RU

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.